medications were stopped. Vesicles were swabbed and sent for HSV PCR (negative) and VZV PCR (positive). She deteriorated clinically. CRP rose to 140 mg/l and a repeat chest X-ray showed diffuse nodular shadowing throughout both lung fields consistent with varicella pneumonitis. Repeated IgG level was 4.7. Clarithromycin was switched to levofloxacin following advice from microbiology and a decision was made to treat with human normal immunoglobulin as per chapter 7 of the government immunoglobulin handbook. She subsequently made a gradual improvement and was discharged 9 days after admission. She soon developed a flare of colitis requiring reintroduction of immunosuppressive therapy. Conclusion: Varicella in patients with prior immunity is rare but patients on immunosuppressive therapy are at increased risk. Such patients should be made aware of this possibility. Our patient may have been at increased risk because of hypogammaglobulinaemia, the incidence of which may be rising with increased use of combination DMARDS and sequential biologic therapy. Best practice following a varicella contact in patients with prior immunity remains unclear. Some manufacturers of biologics (including adalimumab) advise to withhold treatment following a significant contact. The immunoglobulin handbook advises against the use of VZV-specific immunoglobulin in immunosuppressed patients with detectable antibody but to consider the use of human normal immunoglobulin in patients with severe varicella disease in this setting. Disclosure statement: The author has declared no conflicts of interest.
